NEW YORK – ERS Genomics said on Tuesday that it has signed a licensing agreement granting Aelian Biotechnology access to its CRISPR-Cas9 patent portfolio to support Aelian's commercial functional genomic screening platform.
Aelian, based in Vienna, combines CRISPR-Cas9 screening techniques with single-cell sequencing to identify and investigate disease targets and drug mechanisms of action.